South America Virology Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Diagnostic Test, Viral Infection Controlling Techniques, Antiviral Therapeutics, and Interferons), Application (Skin and Soft Tissue Infections, Respiratory Tract Infections, GI Tract Infections, Sexually Transmitted Diseases, Urinary Tract Infection, and Others), and End User (Hospitals, Diagnostic Laboratories, Pharmaceutical and Biotechnological Companies, and Research and Academic Institutes)
Market Introduction
South and America (SAM) region consists of Brazil, Argentina, and the rest of South America. The growth of the virology market can be attributed to increasing research and development investment by private and public organizations. Also, increasing incidence of HIV, hepatitis, and viral infections is driving the adoption of various therapeutics in coming years. Brazil has made huge strides in the healthcare sector owing to increasing healthcare expenditure. As per the International Trade Administration (ITA), Brazil is the largest healthcare market in Latin America and spends 9.1% of its GDP on healthcare. Brazil is currently facing one of the biggest public health crises. In addition, the previous epidemics caused by the Zika virus (ZIKV) coexist in Brazil has increased the burden on the health sector. The outbreak of Zika infection began in Brazil in 2015. In 2019, a total of 10,768 cases of Zika infection were identified in Brazil, and in 2020 the health system was severely hit by the COVID-19 in the country. The recent virus outbreaks are paving the way for more investment in research in infectious disease, further driving the virology market. Also, The HIV and AIDS epidemic in Brazil is stable, with a prevalence in the general population of 0.5%. As per the Avert Organization, in 2019, around 920,000 people were living with HIV, and around 48,000 new infections were recorded. Many steps have been taken by the country with regards to HIV prevalence, driving the virology market. For instance, in 2017, Brazil started providing dolutegravir (DTG) to 100,000 people. Thus, increasing healthcare expenditure and the adoption of new treatments drive market growth in the forecast period. Rise in prevalence of viral infectious diseases is the major factor driving the growth of the SAM virology market.
COVID-19 has created shock waves with severe health, economic and social consequences, which will affect many countries in South America in the future. The COVID-19 pandemic has brought the risk of major disease outbreaks and highlighted countries’ lack of preparedness to fight them. Climate change, urbanization, and the lack of water and sanitation are contributing to fast-spreading outbreaks. Argentina was already in a fragile socio-economic situation before the COVID-19. According to the National Institute of Statistics and Censuses (INDEC), economic activity fell by 10.3% in May 2020, while annual inflation reached 42.8% in June 2020. The fragile health systems in many of these countries and their limited means to finance or drive vaccine development on their own have also put the large population at heightened risk. The COVID-19 pandemic has disrupted healthcare services across South America. For instance, in Guatemala, the COVID-19 has severely impacted HIV services; HIV testing decreased by 54.7% in 2020. As per the PAHO, since the onset of the pandemic, the number of people being tested for HIV in Latin America has dropped sharply. COVID-19 is expected to exacerbate this situation, especially in countries with fragile health systems.
Get more information on this report :
Market Overview and Dynamics
The virology market in SAM is expected to grow from US$ 254.48 million in 2021 to US$ 314.27 million by 2028; it is estimated to grow at a CAGR of 3.1% from 2021 to 2028. Countries such as Argentina and Chile are attractive outsourcing locations for the pharmaceutical and biopharmaceutical industries across the region. Low manufacturing and operating costs and recent growth in the pharmaceutical industry in Argentina and Chile are key factors driving the growth of the virology-related markets in these countries. Moreover, the growing domestic market and its pipelines are opening new access for the manufacturing of generic drugs in the region. In addition, several contract-based organizations are expanding their manufacturing capacities in European nations to meet the rising demand for products, such as vaccines. Thus, the emerging markets are likely to create lucrative opportunities for the growth of the virology market in the coming years across the SAM region.
Key Market Segments
The SAM virology market is segmented on the bases of type, application, end user, and country. Based on type, the market is segmented into diagnostic test, viral infection controlling techniques, antiviral therapeutics, and interferons. The antiviral therapeutics segment dominated the market in 2020, and viral infection controlling techniques segment is expected to be the fastest growing during the forecast period. The diagnostic test segment is further categorized into DNA virus testing, RNA virus testing, others. Similarly, the viral infection controlling techniques is bifurcated into active prophylaxis, and passive prophylaxis. Likewise, the antiviral therapeutics segmented is categorized into virucidal agents, antiviral agents, immunomodulators, and interferons. On the basis of application, the virology market is segmented into skin and soft tissue infections, respiratory tract infections, GI tract infections, sexually transmitted diseases, urinary tract infections, and others. The respiratory tract infections segment dominated the market in 2020, and is expected to be the fastest growing during the forecast period. On the basis of end user, the virology market is segmented into hospitals, diagnostic laboratories, pharmaceutical and biotechnological companies, and research and academic institutes. The hospitals segment dominated the market in 2020, and diagnostic laboratories segment is expected to be the fastest growing during the forecast period.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the virology market in SAM are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; AbbVie Inc.; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline Plc; Illumina, Inc.; Johnson and Johnson Services, Inc.; QIAGEN; Siemens AG; and Thermo Fisher Scientific Inc. are among others.
Reasons to buy report
- To understand the SAM virology market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for SAM virology market
- Efficiently plan M&A and partnership deals in SAM virology market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form SAM virology market
- Obtain market revenue forecast for market by various segments from 2021-2028 in SAM region.
SAM Virology Market Segmentation
SAM Virology Market -By Type
- Diagnostic Test
- DNA Virus Testing
- RNA Virus Testing
- Others
- Viral Infection Controlling Techniques
- Active Prophylaxis
- Passive Prophylaxis
- Antiviral Therapeutics
- Virucidal Agents
- Antiviral Agents
- Immunomodulators
- Interferons
SAM Virology Market -By Application
- Skin and Soft Tissue Infections
- Respiratory Tract Infections
- GI Tract Infections
- Sexually Transmitted Diseases
- Urinary Tract Infections
- Others
SAM Virology Market -By End User
- Hospitals
- Diagnostic Laboratories
- Pharmaceutical and Biotechnological Companies
- Research and Academic Institutes
SAM Virology Market -By Country
- Brazil
- Argentina
- Rest of SAM
SAM Virology Market -Company Profiles
- Abbott
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Illumina, Inc.
- Johnson and Johnson Services, Inc.
- QIAGEN
- Siemens AG
- Thermo Fisher Scientific Inc.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 SAM Virology Market – By Type
1.3.2 SAM Virology Market – By Application
1.3.3 SAM Virology Market – By End User
1.3.4 SAM Virology Market– By Country
2. SAM Virology Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SAM Virology Market– Market Landscape
4.1 Overview
4.2 SAM PEST Analysis
4.3 Experts Opinion
5. SAM Virology Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Viral Infectious Diseases
5.1.2 Surging Product Launches
5.2 Market Restraints
5.2.1 Availability of Alternative Products and High Cost of Production of Products
5.3 Market Opportunities
5.3.1 Immense Growth Potential in Emerging Economies
5.4 Future Trends
5.4.1 Continuous Demand for Cost-Effective Products
5.5 Impact Analysis
6. Virology Market– SAM Analysis
6.1 SAM Virology Market Revenue Forecast and Analysis
7. SAM Virology Market Analysis – By Type
7.1 Overview
7.2 SAM Virology Market Revenue Share, by Type (2021 and 2028)
7.3 Diagnostic Test
7.3.1 Overview
7.3.2 Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Deoxyribonucleic Acid (DNA) Virus Testing
7.3.2.1.1 Overview
7.3.2.1.2 DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Ribonucleic Acid (RNA) Virus Testing
7.3.2.2.1 Overview
7.3.2.2.2 RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Others
7.3.2.3.1 Overview
7.3.2.3.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Viral Infection Controlling Techniques
7.4.1 Overview
7.4.2 Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Active Prophylaxis
7.4.2.1.1 Overview
7.4.2.1.2 Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Passive Prophylaxis
7.4.2.2.1 Overview
7.4.2.2.2 Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Antiviral Therapeutics
7.5.1 Overview
7.5.2 Antiviral Therapeutics: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Virucidal Agents
7.5.2.1.1 Overview
7.5.2.1.2 Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Antiviral Agents
7.5.2.2.1 Overview
7.5.2.2.2 Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Immunomodulators
7.5.2.3.1 Overview
7.5.2.3.2 Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Interferons
7.6.1 Overview
7.6.2 Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8. SAM Virology Market Analysis – By Application
8.1 Overview
8.2 SAM Virology Market, by Application 2021 & 2028 (%)
8.3 Skin and Soft Tissue Infections
8.3.1 Overview
8.3.2 Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Respiratory Tract Infections
8.4.1 Overview
8.4.2 Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.5 GI Tract Infections
8.5.1 Overview
8.5.2 GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Sexually Transmitted Diseases
8.6.1 Overview
8.6.2 Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Urinary Tract Infections
8.7.1 Overview
8.7.2 Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9. SAM Virology Market Analysis – By End User
9.1 Overview
9.2 SAM Virology Market Revenue Share, by End User (2021 and 2028)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Diagnostic Laboratories
9.4.1 Overview
9.4.2 Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Pharmaceutical and Biotechnological Companies
9.5.1 Overview
9.5.2 Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Research and Academic Institutes
9.6.1 Overview
9.6.2 Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)
10. SAM Virology Market – Country Analysis
10.1.1 Overview
10.1.2 South America: Virology Market, by Country, 2021 & 2028 (%)
10.1.2.1 Brazil: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.1 Brazil: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.2 Brazil: Virology Market, By Type, 2019–2028 (USD Million)
10.1.2.1.2.1 Brazil: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.1.2.2 Brazil: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.1.2.3 Brazil: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.1.3 Brazil: Virology Market, by Application, 2019–2028 (USD Million)
10.1.2.1.4 Brazil: Virology Market, by End User, 2019–2028 (USD Million)
10.1.2.2 Argentina: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.1 Argentina: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.2 Argentina: Virology Market, By Type, 2019–2028 (USD Million)
10.1.2.2.2.1 Argentina: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.2.2.2 Argentina: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.2.2.3 Argentina: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.2.3 Argentina: Virology Market, by Application, 2019–2028 (USD Million)
10.1.2.2.4 Argentina: Virology Market, by End User, 2019–2028 (USD Million)
10.1.2.3 Rest of South America: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.1 Rest of South America: Virology Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.2 Rest of South America: Virology Market, By Type, 2019–2028 (USD Million)
10.1.2.3.2.1 Rest of South America: Virology Market, by Diagnostic Test, 2019–2028 (USD Million)
10.1.2.3.2.2 Rest of South America: Virology Market, by Viral Infection Controlling Techniques, 2019–2028 (USD Million)
10.1.2.3.2.3 Rest of South America: Virology Market, by Antiviral Therapeutics, 2019–2028 (USD Million)
10.1.2.3.3 Rest of South America: Virology Market, by Application, 2019–2028 (USD Million)
10.1.2.3.4 Rest of South America: Virology Market, by End User, 2019–2028 (USD Million)
11. Impact of COVID-19 Pandemic on SAM Virology Market
11.1 Overview
12. SAM Virology Market–Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Abbott
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Johnson and Johnson Services, Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 F. HOFFMANN-LA ROCHE LTD.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 THERMO FISHER SCIENTIFIC INC.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 QIAGEN
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Illumina, Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 GlaxoSmithKline Plc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 AbbVie Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Gilead Sciences, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. SAM Virology Market Revenue and Forecast to 2028 (US$ Million)
Table 2. Brazil: Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 3. Brazil Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 4. Brazil Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 5. Brazil Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 6. Brazil: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 7. Brazil: Virology Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 8. Argentina: Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 9. Argentina Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 10. Argentina Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million)
Table 11. Argentina Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 12. Argentina: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 13. Argentina: Virology Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 14. Rest of South America: Virology Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 15. Rest of South America Virology Market, by Diagnostic Test– Revenue and Forecast to 2028 (USD Million)
Table 16. Rest of South America Virology Market, by Viral Infection Controlling Techniques– Revenue and Forecast to 2028 (USD Million
Table 17. Rest of South America Virology Market, by Antiviral Therapeutics– Revenue and Forecast to 2028 (USD Million)
Table 18. Rest of South America: Virology Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 19. Rest of South America: Virology Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 20. Organic Developments Done by Companies
Table 21. Inorganic Developments Done by Companies
Table 22. Glossary of Terms, SAM Virology Market
LIST OF FIGURES
Figure 1. SAM Virology Market Segmentation
Figure 2. SAM Virology Segmentation, By Country
Figure 3. SAM Virology Market Overview
Figure 4. Antiviral Therapeutics Held the Largest Share of the Type Segment in SAM Virology Market
Figure 5. Respiratory Tract Infections Held the Largest Share of the Application Segment in SAM Virology Market
Figure 6. Brazil to Show Significant Growth During Forecast Period
Figure 7. SAM PEST Analysis
Figure 8. SAM Virology Market: Impact Analysis of Drivers and Restraints
Figure 9. SAM Virology Market– Revenue Forecast and Analysis – 2019- 2028
Figure 10. SAM Virology Market Revenue Share, by Type (2021 and 2028)
Figure 11. SAM Diagnostic Test: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. SAM DNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. SAM RNA Virus Testing: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. SAM Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. SAM Viral Infection Controlling Techniques: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. SAM Active Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. SAM Passive Prophylaxis: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. SAM Antiviral Therapeutics: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. SAM Virucidal Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. SAM Antiviral Agents: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. SAM Immunomodulators: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. SAM Interferons: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. SAM Virology Market, by Application 2021 & 2028 (%)
Figure 24. SAM Skin and Soft Tissue Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. SAM Respiratory Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. SAM GI Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. SAM Sexually Transmitted Diseases: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. SAM Urinary Tract Infections: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. SAM Others: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. SAM Virology Market Revenue Share, by End User (2021 and 2028)
Figure 31. SAM Hospitals: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. SAM Diagnostic Laboratories: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. SAM Pharmaceutical and Biotechnological Companies: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. SAM Research and Academic Institutes: Virology Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. South America: Virology Market, by Key Country – Revenue (2021) (USD Million)
Figure 36. South America: Virology Market, by Country, 2021 & 2028 (%)
Figure 37. Brazil: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. Argentina: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. Rest of South America: Virology Market – Revenue and Forecast to 2028 (USD Million)
Figure 40. Impact of COVID-19 Pandemic on Virology Market in SAM Countries
- Abbott
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline Plc
- Illumina, Inc.
- Johnson and Johnson Services, Inc.
- QIAGEN
- Siemens AG
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the SAM Virology market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the SAM Virology market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the Virology market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution